Please assess the completion status of the following clinical trial:

Trial Title: Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive. ALK positivity must have been determined by a validated fluorescence in situ hybridization (FISH) test (recommended probe, Vysis ALK Break-Apart Probe) or a validated immunohistochemistry (IHC) test (recommended antibody, clone D5F3)~* Participant had received two prior systemic lines of therapy, which must have included one line of platinum-based chemotherapy and one line of crizotinib~* Prior CNS or leptomeningeal metastases allowed if asymptomatic~* Participants with symptomatic CNS metastases for whom radiotherapy is not an option will be allowed to participate in this study~* Measurable disease by RECIST Version 1.1 prior to the administration of study treatment~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2~* For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment~Exclusion Criteria:~* Participants with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal \[GI\] cancer by endoscopic resection or in situ carcinoma of the cervix)~* Participants who have received any previous ALK inhibitor other than crizotinib~* Any GI disorder that may affect absorption of oral medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alectinib (Type: EXPERIMENTAL): Participants will receive oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Premetrexed/Docetaxel (Type: ACTIVE_COMPARATOR): Participants will receive chemotherapy with either pemetrexed (500 milligrams per square meter \[mg/m\^2\] of body surface area) or docetaxel (75 mg/m\^2) intravenously.

Based on this trial design, predict the completion outcome and termination type (if applicable).